From my research it looks like a total of 11 new Patents were granted to Mesoblast during 2020 for those that are interested - as you can see, some of them take years from the "File Date" before they are granted and some only take a handful of months .... anyway a bit of trivia while we wait for the CLBP readouts
Method of treating graft versus host disease
Patent number: 10849932 Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom. Type: Grant Filed: September 14, 2018 Date of Patent: December 1, 2020 Assignee: MESOBLAST, INC. Inventors: Silviu Itescu, Michael David Schuster
Mesenchymal stem cells and uses therefor
Patent number: 10828334 Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount. Type: Grant Filed: March 11, 2020 Date of Patent: November 10, 2020 Assignee: Mesoblast International Sárl Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
Mesenchymal stem cells and uses therefor
Patent number: 10729727 Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount. Type: Grant Filed: November 29, 2018 Date of Patent: August 4, 2020 Assignee: Mesoblast International Sárl Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
Mesenchymal stem cells and uses therefor
Patent number: 10716814 Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount. Type: Grant Filed: November 30, 2018 Date of Patent: July 21, 2020 Assignee: Mesoblast International Sàrl Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
Methods of treating or preventing respiratory conditions
Patent number: 10688134 Abstract: The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom. Type: Grant Filed: July 16, 2018 Date of Patent: June 23, 2020 Assignee: Mesoblast, Inc. Inventors: Silviu Itescu, Ravi Krishnan, Peter Ghosh
Mesenchymal stem cells and uses therefor
Patent number: 10668101 Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount. Type: Grant Filed: December 23, 2013 Date of Patent: June 2, 2020 Assignee: MESOBLAST INTERNATIONAL SÁRL Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
Patent number: 10662234 Abstract: The present invention features methods for treating or ameliorating tissue damage using intravenous administration of compositions that include stromal cell derived factor-1 (SDF-1) peptides or mutant SDF-1 peptides that have been mutated to make them resistant to protease digestion, but which retain chemoattractant activity. Systemic delivery, and specifically intravenous (“IV” delivery, of SDF-1 and protease resistant SDF-1 mutants is very effective for the treatment of tissue damage. Type: Grant Filed: June 6, 2012 Date of Patent: May 26, 2020 Assignee: Mesoblast International Sàrl Inventors: Anthony Sandrasagra, Weitao Wu
Treatment of immune disorders
Patent number: 10624930 Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes. Type: Grant Filed: June 1, 2015 Date of Patent: April 21, 2020 Assignee: MESOBLAST INTERNATIONAL SARL Inventors: Silviu Itescu, Paul Simmons
Methods of treating or preventing rheumatic disease
Patent number: 10596199 Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom. Type: Grant Filed: April 17, 2018 Date of Patent: March 24, 2020 Assignee: MESOBLAST, INC. Inventors: Peter Ghosh, Silviu Itescu
Enhanced MSC preparation
Patent number: 10550369 Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof. Type: Grant Filed: April 4, 2018 Date of Patent: February 4, 2020 Assignee: Mesoblast International Sarl Inventors: Samson Tom, Christopher Ton, Alla Danilkovitch
Method of increasing proliferation of bone marrow mononuclear cells expressing STRO1-
Patent number: 10544394 Abstract: The present invention relates to methods of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) and/or progeny derived therefrom in vitro or in vivo comprising exposing the MPC or progeny to SDF-1 or analog thereof. The invention also relates to compositions comprising isolated MPCs or progeny derived therefrom and SDF-1 or analogues thereof. The present invention also relates to using such methods and compositions for ex vivo or in vivo bone formation in mammals. Type: Grant Filed: August 27, 2014 Date of Patent: January 28, 2020 Assignee: Mesoblast, Inc. Inventors: Stan Gronthos, Andrew Christopher William Zannettino
MSB Price at posting:
$2.50 Sentiment: Buy Disclosure: Held
delivery, of SDF-1 and protease resistant SDF-1 mutants is very effective for the treatment of tissue damage.
(20min delay)